JANX News and Press, Janux Therapeutics Inc. From 07/17/23

2023-07-17 08:59:08 ET Biopharmaceutical company Janux Therapeutics ( NASDAQ: JANX ) said on Monday that it has priced an ~$60M underwritten offering of 4.2M shares and pre-funded warrants to purchase 583.45K shares. The shares are being sold at $12.46 per share and the pre-fu...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers ...

2023-06-22 12:14:19 ET The major market averages trade significantly higher on the year as investors approach the halfway point of 2023. However, not every stock finds itself on easy street with some market participants shorting popular names. As a frame of reference, short interest ref...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

-First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -$316.9 million in cash and cash equivalents and short-term investments at end of first q...

2023-05-09 04:02:31 ET Summary Despite the recent rebound, US-listed biotech stocks valuations are still "down to earth" compared to the strong recovery from the Covid-19 crisis. Relatively low market valuations offer an opportunity to add to positions in biotechnology stocks with...

2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...